# Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

> **NCT04987931** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 84 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT04987931
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-20
- **Primary completion:** 2021-10-11
- **Final completion:** 2021-10-11
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987931, "Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04987931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*